×
For best experience we recommend to activate Javascript in your browser.
Recombinant TNFRSF12A (Enavatuzumab Biosimilar) antibody
The Human Monoclonal anti-TNFRSF12A (Enavatuzumab Biosimilar) antibody has been validated for ELISA, FACS, BLI, Func and SPR. It is suitable to detect TNFRSF12A (Enavatuzumab Biosimilar) in samples from Human.
Quick Overview for Recombinant TNFRSF12A (Enavatuzumab Biosimilar) antibody (ABIN7581715)
Target
TNFRSF12A (Enavatuzumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
All hosts for TNFRSF12A (Enavatuzumab Biosimilar) antibodies
Human
Clonality
All clonalities for TNFRSF12A (Enavatuzumab Biosimilar) antibodies
Monoclonal
Conjugate
All conjugates for TNFRSF12A (Enavatuzumab Biosimilar) antibodies
This TNFRSF12A (Enavatuzumab Biosimilar) antibody is un-conjugated
Application
ELISA, Flow Cytometry (FACS), Bio-Layer Interferometry (BLI), Functional Studies (Func), Surface Plasmon Resonance (SPR)
Product Details anti-TNFRSF12A (Enavatuzumab Biosimilar) Antibody
(hide)
Expression System
CHO Cells
Purpose
Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab)
Characteristics
Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
Purity
>95 %
Isotype
IgG1
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Lyophilized
Concentration
1 mg/mL
Buffer
25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
Storage
4 °C,-80 °C
Storage Comment
+4°C,-80°C
Target Details for TNFRSF12A (Enavatuzumab Biosimilar)
(hide)
Target
TNFRSF12A (Enavatuzumab Biosimilar)
Target Type
Biosimilar
Molecular Weight
145.5 kDa
UniProt
Q9NP84
Recently viewed
(hide)
Chat with us , powered by LiveChat